Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00230776 · ClinicalTrials.gov registry record · Phase 3

A Controlled Pregabalin Trial In Fibromyalgia

A Phase 3 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.

Completed
Registry status
Phase 3
Development phase
740
Enrollment target

NCT00230776: Completed Phase 3 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.

NCT00230776 is a Phase 3 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 740 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00230776, a Phase 3 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.

COMPLETED
Registry status
Phase 3
Development phase
740 participants
Enrollment target

Study Summary

To evaluate the efficacy and safety of pregabalin compared with placebo for the relief of pain associated with fibromyalgia and improvement of function of patients with fibromyalgia

Interventions

  • DRUG placebo
  • DRUG pregabalin

Trial Details

FieldValue
Enrollment Target 740 participants
Start Date 2005-10
Est. Completion 2006-07
Phase Phase 3

What the finished NCT00230776 record still lists

NCT00230776 is an interventional study that assigns participants to a tested intervention. The registered 740 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.

The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.

NCT00230776 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00230776 about?

NCT00230776 is a clinical study titled "A Controlled Pregabalin Trial In Fibromyalgia". To evaluate the efficacy and safety of pregabalin compared with placebo for the relief of pain associated with fibromyalgia and improvement of function of patients with fibromyalgia

What is the current status of trial NCT00230776?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 740 participants. The study started on 2005-10. Estimated completion is 2006-07.

What interventions are being tested in trial NCT00230776?

The interventions under investigation include: placebo (DRUG), pregabalin (DRUG).

Who is sponsoring clinical trial NCT00230776?

This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00230776's enrollment target sits among peer trials

740 477th of 2000 higher than 1,523 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03963622 · 740 participants · NA

    Careful Ventilation in Acute Respiratory Distress Syndrome (COVID-19 and Non-COVID-19)

  • NCT04074135 · 740 participants · Phase 2

    Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

  • NCT05215340 · 740 participants · Phase 3

    Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

  • NCT06172478 · 740 participants · Phase 2

    A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00230776, the US trial registry maintained by the National Library of Medicine. NCT00230776 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.